For studies on the intrahepatic engraftment of transplanted hepatocytes, labeling of donor cells is necessary. Current labeling techniques enable only short-term monitoring of engraftment. In the present study, we describe the use of 5-bromo-2'-deoxyuridine (BrdU) for a more permanent hepatocyte labeling. BrdU is stably incorporated into replicating DNA; consequently, BrdU labeling was performed in regenerating livers. In 10 Lewis rats, a two-thirds partial hepatectomy was performed, followed by continuous, low-dose BrdU administration. This approach provided a fraction of 89+/-1.5% BrdU-labeled donor hepatocytes, without influencing the efficacy of the ensuing isolation of donor hepatocytes. Subsequently, +/-1 x 10(7) isolated hepatocytes were transplanted either intraportally or intrasplenically into syngeneic recipients, and the engraftment of transplanted cells was evaluated in liver lobes at successive time intervals after transplantation. BrdU-positive hepatocytes could be identified and quantitated in recipient livers up to 180 days after transplantation. Repetitive quantitative assessments over time revealed an initial, drastic loss of transplanted cells (<24 hr), followed by a stabilization at approximately 7% of the injected cells. Histological monitoring showed that during this period (<48 hr) the transplanted cells migrate from the portal venules to the liver parenchyma. In recipient livers a homogeneous lobe distribution of hepatocyte engraftment was found 30 days after both intraportal and intrasplenic transplantation. Moreover, no significant difference between the intrahepatic liver cell engraftment of the two transplantation routes was demonstrated. In conclusion, the BrdU-labeling technique of donor hepatocytes enables long-term histological monitoring and quantitative evaluation of the engraftment of transplanted liver cells in recipient livers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00007890-199702270-00005 | DOI Listing |
Front Pharmacol
January 2025
Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Objective: The expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the toxicity associated with cell collection methods. Umbilical cord blood (CB) represents a readily accessible source of hematopoietic stem and progenitor cells (HSPCs); however, the cell dose obtainable from a single cord blood unit is frequently insufficient. This limitation can be addressed by enhancing the potency of HSPCs, specifically their capacity to reconstitute hematopoiesis.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) are mainstay prophylactic treatment options for graft-versus-host disease (GVHD), widely used in haploidentical stem cell transplantation. Due to a lack of prospective studies, a number of retrospective comparisons have yielded different conclusions as to which prophylaxis regimen is superior. We performed a meta-analysis of these studies to get more informed and comprehensive decisions from clinicians.
View Article and Find Full Text PDFHematol Rep
January 2025
Operations Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates.
The outcome of refractory/relapsed systemic Anaplastic Large Cell Lymphoma (R/R-sALCL), especially for anaplastic lymphoma kinase-1 (ALK-1)-negative disease, remains dismal even after autologous hematopoietic stem cell transplantation (AHSCT). The intensification of both salvage and conditioning regimens, without increasing the toxicity, could improve the outcome of AHSCT in R/R-sALCL. Based on the successful experience of the incorporation of antiD20 monoclonal antibodies in the treatment of B-Cell Lymphomas, we designed a salvage and conditioning regimen incorporating the antiCD30-conjugated antibody (Brentuximab Vedotin, BV) to standard chemotherapy regimens, and we describe herein the clinical course of a patient with AKL-ve, R/R-sALCL, who received salvage regimen BV + DHAP, followed by AHSCT with preparative regimen consisted of BV plus standard BEAM.
View Article and Find Full Text PDFFront Immunol
January 2025
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: With recent advances in clinical practice, including the use of reduced-toxicity conditioning regimens and innovative approaches such as ex vivo TCRαβ/CD19 depletion of haploidentical donor stem cells or post-transplant cyclophosphamide (PTCY), hematopoietic stem cell transplantation (HSCT) has emerged as a curative treatment option for a growing population of patients with inborn errors of immunity (IEI). However, despite these promising developments, graft failure (GF) remains a significant concern associated with HSCT in these patients. Although a second HSCT is the only established salvage therapy for patients who experience GF, there are no uniform, standardized strategies for performing these second transplants.
View Article and Find Full Text PDFArtif Organs
January 2025
Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.
Intrahepatic islet transplantation is a promising strategy for β-cell replacement therapy in the treatment of Type 1 Diabetes. However, several obstacles hinder the long-term efficacy of this therapy. A major challenge is the scarcity of donor organs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!